Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.
Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need that is backed by University of Cambridge’s patient capital fund Cambridge Innovation Capital (CIC), has filed for an $86m initial public offering on the Nasdaq Global Market.
Founded in 2009, Bicycle Therapeutics is developing treatments for conditions with a high unmet need. It is initially focusing on oncology but plans to also target other disease areas, and is collaborating with biopharmaceutical firms in antibacterial, cardiovascular,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
